Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Al-Khatib

Showing results (121-130 of 143) with videos related to

Pageof 15
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 17, 2021
Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta VariantLaith J Abu-Raddad, Hiam Chemaitelly, Houssein H Ayoub, et al.
The New England Journal of Medicine|March 9, 2022
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in QatarLaith J Abu-Raddad, Hiam Chemaitelly, Houssein H Ayoub, et al.
BMJ Public Health|February 28, 2025
Turning point in COVID-19 severity and fatality during the pandemic: a national cohort study in QatarHiam Chemaitelly, Houssein H Ayoub, Jeremy Samuel Faust, et al.
Nature Communications|June 2, 2022
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in QatarHiam Chemaitelly, Houssein H Ayoub, Sawsan AlMukdad, et al.
The New England Journal of Medicine|October 6, 2021
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in QatarHiam Chemaitelly, Patrick Tang, Mohammad R Hasan, et al.
Science Advances|October 4, 2023
History of primary-series and booster vaccination and protection against Omicron reinfectionHiam Chemaitelly, Houssein H Ayoub, Patrick Tang, et al.
Ebiomedicine|July 29, 2023
Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational studyHeba N Altarawneh, Hiam Chemaitelly, Houssein H Ayoub, et al.
The New England Journal of Medicine|October 5, 2022
Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 SubvariantsHeba N Altarawneh, Hiam Chemaitelly, Houssein H Ayoub, et al.
The New England Journal of Medicine|January 18, 2023
Protection against Reinfection with the Omicron BA.2.75 SubvariantHiam Chemaitelly, Patrick Tang, Peter Coyle, et al.
Nature Medicine|July 10, 2021
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in QatarHiam Chemaitelly, Hadi M Yassine, Fatiha M Benslimane, et al.
Pageof 15

Showing results (121-130 of 143) with videos related to

Sort By:
Pageof 15
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 17, 2021
Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta VariantLaith J Abu-Raddad, Hiam Chemaitelly, Houssein H Ayoub, et al.
The New England Journal of Medicine|March 9, 2022
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in QatarLaith J Abu-Raddad, Hiam Chemaitelly, Houssein H Ayoub, et al.
BMJ Public Health|February 28, 2025
Turning point in COVID-19 severity and fatality during the pandemic: a national cohort study in QatarHiam Chemaitelly, Houssein H Ayoub, Jeremy Samuel Faust, et al.
Nature Communications|June 2, 2022
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in QatarHiam Chemaitelly, Houssein H Ayoub, Sawsan AlMukdad, et al.
The New England Journal of Medicine|October 6, 2021
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in QatarHiam Chemaitelly, Patrick Tang, Mohammad R Hasan, et al.
Science Advances|October 4, 2023
History of primary-series and booster vaccination and protection against Omicron reinfectionHiam Chemaitelly, Houssein H Ayoub, Patrick Tang, et al.
Ebiomedicine|July 29, 2023
Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational studyHeba N Altarawneh, Hiam Chemaitelly, Houssein H Ayoub, et al.
The New England Journal of Medicine|October 5, 2022
Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 SubvariantsHeba N Altarawneh, Hiam Chemaitelly, Houssein H Ayoub, et al.
The New England Journal of Medicine|January 18, 2023
Protection against Reinfection with the Omicron BA.2.75 SubvariantHiam Chemaitelly, Patrick Tang, Peter Coyle, et al.
Nature Medicine|July 10, 2021
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in QatarHiam Chemaitelly, Hadi M Yassine, Fatiha M Benslimane, et al.
Pageof 15